Zimberelimab, CARBOPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, CISPLATIN , PACLITAXEL , Abraxane 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion
GS-US-626-6216
Phase 3 small_molecule active
Quick answer
Zimberelimab, CARBOPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, CISPLATIN , PACLITAXEL , Abraxane 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion for Metastatic Non–Small Cell Lung Cancer is a Phase 3 program (small_molecule) at Gilead Sciences International Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Gilead Sciences International Limited
- Indication
- Metastatic Non–Small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active